Trials / Unknown
UnknownNCT05308784
A Survey of Physician and Molecular Tumor Board Perspectives on the Clinical Utility and Usability of Cellworks Singula™ and Ventura™ Reports in Facilitating Patient Treatment Decisions for Pan-Cancer Patients
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 730 (estimated)
- Sponsor
- Avera McKennan Hospital & University Health Center · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the benefit of Cellworks Singula™ and Ventura™ reports on physician and molecular tumor board treatment recommendations across a large set of pan-cancer indications. Cellworks reports aim to provide NGS-based therapy recommendations to aid the decision-making of patients, physicians, and molecular tumor boards.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Cellworks Singula and Ventura reports | Personalized drug match reports based on patients' genomic aberration. |
Timeline
- Start date
- 2022-01-01
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
- First posted
- 2022-04-04
- Last updated
- 2023-07-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05308784. Inclusion in this directory is not an endorsement.